A deletion of the transcription factor SOX9 gene in the mice intestine affects the morphology of the colon epithelium and leads to hyperplasia. Nevertheless, direct transcriptional targets of SOX9 in this tissue are still unknown. A microarray analysis identified the tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) as a possible SOX9 target gene and we demonstrate here that SOX9 upregulates CEA-CAM1 in human colonic cells. Moreover, CEACAM1 expression is reduced in colon of SOX9-deficient mouse, suggesting an important function for SOX9 in the transcriptional activation of the CEACAM1 gene. We further identified SOX9-binding sequences in the human and rat CEACAM1 promoters, and an electrophoretic mobility shift together with a chromatin immunoprecipitation provided an additional evidence of the SOX9 binding to the human promoter. In addition, we established that histone acyl-transferase p300 behaves as an SOX9 coactivator of the rat and human CEACAM1 promoters. These results highlight CEACAM1 as the first direct target of SOX9 identified in the colon epithelium.
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The HMG box transcription factor SOX9 is expressed in proliferating cells at the bottom third of the colon epithelium crypts (Blache et al., 2004; Jay et al., 2005) . An inactivation of the SOX9 gene in the intestine epithelium severely alters the morphology of the colon epithelium with the appearance of hyperplasia and local crypt dysplasia suggesting a regulating function for SOX9 in cell proliferation (Bastide et al., 2007) . Moreover, SOX9 is expressed in the colon tumors (Blache et al., 2004; Jay et al., 2005; Lu et al., 2006) and colon carcinoma cell lines (Blache et al., 2004) . However, for still unidentified reasons, SOX9 endogenous activity is weak in the tumoral HT29.Cl16E and SW480 human colon cell lines (Darido et al., 2008) , suggesting a reduction of SOX9 activity in colon tumor cells. Nevertheless, direct transcriptional targets of SOX9 in colon are still unknown. To find out possible targets of SOX9, we carried out a microarray analysis (accession number E-MEXP-859), and the tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) was identified as a possible SOX9 gene target in colon cells. CEACAM1 is a multifunctional, homophilic adhesion receptor molecule, the most ancestral member of the carcinoembryonic antigen (CEA) family, which is a subfamily of the immunoglobulin superfamily. Its transmembrane signaling leads to a variety of cellular responses including the regulation of proliferation, apoptosis, differentiation, tumor growth and modulation of the innate and adaptive immune responses (Kuespert et al., 2006) . A defect of CEACAM1 expression is involved in early colorectal tumorigenesis (Nittka et al., 2004) , and mice with a deleted CEACAM1 gene are more susceptible to tumor development in the colon upon carcinogen treatment than their littermate control (Leung et al., 2006) . CEACAM1 generates apoptotic signals implicated in the maintenance of the monolayer of colon epithelial cells (Nittka et al., 2004) . The mechanisms involved in the regulation of CEACAM1 gene expression are, however, poorly understood, except that the silencing of its gene is not because of genetic alterations in either pre-cancerous or cancer tissue. In this study, we describe a SOX9-dependant regulation of the human, rat and mouse CEACAM1 promoters despite no significant homology among these promoters. This study points out CEACAM1 as the first direct transcriptional target of SOX9 identified in the intestine epithelium.
SOX9 increases CEACAM1 expression in human colonic cells
The HT29Cl.16E colonic cells modified to express a Flag-tagged wild-type SOX9 (HT29Cl.16E-SOX9) upon doxycycline treatment (Jay et al., 2005) were used to Values are plotted as means ± s.e., data were analysed using the Student's t-test, P-values are shown and NS indicates a nonsignificant variation, (n ¼ 3). (b) Western blot analysis of CEACAM1 expression upon doxycycline induction of SOX9 and D206SOX9 after 2 days of culture. CEACAM1 was detected with the mouse monoclonal antibody (MAb 4D1/C2) (Wagener et al., 1983) , SOX9 and DC206SOX9 with the mouse M2 anti-flag monoclonal antibody from Sigma-Aldrich (St Louis, MO, USA). (c) Upregulation of CEACAM1 expression visualized by immunofluorescence after transfection of GFP-SOX9 in HT29.Cl16E and SW480 cells. CEACAM1 was detected with the MAb 4D1/C2 antibody. GFP cDNA was generated by PCR and introduced at the 5 0 end of SOX9 cDNA to produce pcDNA3-GFP-SOX9. Bar, 15 mm. CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcription PCR.
Figure 2 SOX9 activates the human CEACAM1 promoter. (a) HT29.Cl16E cells were transfected with reporter plasmids containing the functional 3.1-kb CEACAM1 promoter, the antisense construct (p3.1aluc), the construct (À2186 to À1091) linked to the CEACAM1 minimal promoter (pPP1.1sDABluc), the construct without the Alu consensus sequences (pSPDABluc) and the minimal promoter (pABsluc), together with the empty pcDNA3 (1 mg) or SOX9 (1 mg) vectors. The arrow represents the transcriptional start site. (b) HT29.Cl16E cells were transfected with the pGL3-Promoter vector containing a fragment (À1597 to À1032) of the human CEACAM1 promoter (H(À1597/À1032)wt luc) or a fragment in which an EcoR1 restriction site substituted the putative SOX9-binding sequence (H(À1597/À1032)eco luc). Fold increases upon SOX9 co-transfection are indicated as means ± s.e., data were analysed using the Student's t-test, P-values are indicated (n ¼ 3). (c) Probes used for EMSA experiments. (d) EMSA for specific binding of the SOX9 protein with the wild-type (WT) oligonucleotide probe corresponding to the SOX9-A-and SOX9-B-binding sites of the human CEACAM1 promoter. EMSA was essentially conducted as that by Zhou et al. (1998) , SOX9 protein was prepared by in vitro translation using TNT T7-coupled reticulocyte lysate (RL) system (Promega, Madison, WI, USA). Cold competition was performed with 60 000 c.p.m. of the WT 32 P-labeled probe and 100 ng of unlabeled WT or mutated probe. m and d indicate SOX9 monomer and SOX9 dimer, respectively. (e) Supershift by the M2 anti-flag monoclonal antibody (0.05 mg) of the complex of SOX9 protein and the WT labeled probe obtained with RL or with nuclear extracts (5 mg of protein) from HT29Cl.16E cells transfected with SOX9 (HT29Cl.16E). Nuclear extracts were prepared with the Active Motif kit. m, d and ss indicate SOX9 monomer, SOX9 dimer and the supershift complex, respectively. (f) Chromatin immunoprecipitation assay for specific binding of SOX9 to the human CEACAM1 promoter was performed using the MAGNA CHIP (Upstate, Millipore Corporation, Temecula, CA, USA). ChIPable chromatin from HT29 cells (Upstate) was amplified by primers spanning the SOX9-binding site before (input) and after immunoprecipitation with the SOX9 antibody. (Forward primer: 5 0 -CCTTCCCAGCCTCTGGTA-3 0 ; reverse primer: 5 0 -GGAGAGAACTGTCCACCA-3 0 ). Control was performed with normal rabbit immunoglobulin. (g) HT29.Cl16E cells were transfected with the 3.1 kb CEACAM1 promoter luciferase reporter plasmid. Empty pcDNA3 (1 mg), SOX9 (1 mg) or SOX9DC206 vectors (1 mg) were co-transfected. Luciferase activities of reporters co-transfected with pcDNA3 empty vector were arbitrarily set to onefold increase. Fold increases are indicated as means ± s.e., data were analysed using the Student's t-test, P-values are indicated (n ¼ 3). CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; EMSA, electrophoretic mobility shift assay. 
observed (Figures 1a and b) , likely because of a dominant negative effect of the DC206SOX9 mutant that inhibits the weak SOX9 endogenous activity. To determine if SOX9 regulated CEACAM1 in another cellular model, both HT29Cl.16E and SW480 cells were transfected with a SOX9-tagged green fluorescent protein (GFP-SOX9) or GFP as a control and CEACAM1 expression was monitored by immunofluorescence. As expected, an overexpression of GFP did not affect the CEACAM1 staining in HT29Cl.16E and SW480 cells, compared with adjacent non-transfected cells (Figure 1c) . In contrast, overexpressing GFP-SOX9 resulted in an increase of CEACAM1 staining indicating that SOX9 upregulates the expression of CEACAM1 in both the cell lines (Figure 1c ).
SOX9 physically binds to the human CEACAM1 promoter
The mechanisms regulating CEACAM1 expression are poorly understood and the transcription factors described to regulate its promoter are distinct between rat and human species (Hauck et al., 1994; Najjar et al., 1996) . The previously described luciferase reporter containing the functional 3.1 kb CEACAM1 human promoter (Hauck et al., 1994 ) (p3.1sluc) was used to study the regulation by SOX9. The basal luciferase activity was increased 2.6-fold when this reporter was co-transfected with SOX9 in HT29Cl.16E cells (Figure 2a) . The antisense construct (p3.1aluc), used as a control, was not affected by SOX9. The luciferase reporter constructed with a (À2186 to À1091) fragment linked to the CEACAM1 minimal promoter (pPP1.1sDABluc) was activated 2.8-fold when cotransfected with SOX9 (Figure 2a) . Two Alu consensus sequences are located approximately between À2275 and À1675 upstream of the starting codon (Figure 2a) . These Alu consensus sequences were not required for SOX9 activity as the pSPDABluc reporter was increased 3.2-fold after SOX9 co-transfection. As the activity of the minimal promoter alone (pABsluc) was not modified by SOX9 co-transfection (Figure 2a) , we concluded that the sequence between À1542 and À1091 probably contains an SOX9-binding site.
Thus, we sought to identify putative SOX9-binding site in the 1542 to À1091 region of the human CEACAM1 promoter. The SOX9-binding enhancer elements identified in the 5 0 regions and/or in first introns of mouse collagen genes COL2A1, COL11A2, COL9A1 and COL9A2 contain paired SOX9-binding sites displaying one or two mismatches with the SOX consensus sequence (A/TA/TCAAA/TG). The two sites are separated by 3 or 4 bp and arranged in opposite orientation to each other. SOX9-binding enhancer elements have been identify in the first intron of the human COL27A1 gene by searching for oppositely oriented pairs of the SOX consensus sequence allowing a maximum of 2-bp mismatch from this consensus (Jenkins et al., 2005) . Using this method, we analysed the (À1542 to À1091) sequence and found the sequence CTCACTGggcCTTTGTT in the position À1418 to À1402. This sequence contains a SOX consensus sequence in the sense orientation with two mismatches (SOX9-A) followed by three nucleotides and a perfect SOX consensus sequence in the antisense orientation (SOX9-B). A fragment (À1597 to À1032) was PCR amplified and cloned into the pGL3-Promoter vector that contains an SV40 promoter upstream of the luciferase gene (H(À1597/À1032)wt luc reporter). The activity of this reporter was increased 2.4-fold when cotransfected with SOX9 (Figure 2b ). We then disrupted the two putative SOX9-binding sequences by a substitution with an EcoR1 restriction site in the (À1597 to À1032) fragment. SOX9 was unable to activate the H(À1597/À1032)eco luc reporter plasmid suggesting that SOX9 regulates CEACAM1 transcription by binding to this enhancer sequence. We performed electrophoretic mobility shift assay to determine whether SOX9 is able to bind these two putative binding sites, SOX9-A and SOX9-B (Figure 2c ). The specific binding of in vitro translated SOX9 with the wild-type labeled probe revealed the formation of two complexes probably due to the binding of SOX9 as a monomer to one site or as a dimer to both sites. We then intended to characterize these binding sites by a cold competition with unlabeled probes displaying mutated binding sites. Competition with the unlabeled wild-type probe suppressed the formation of the monomer and dimer complexes (Figure 2d ). The probe with mutations in SOX9-A suppressed the formation of almost all the dimer complexes and part of the monomer complex whereas the probe with mutations in the SOX9-B sites did not suppress the formation of both complexes. As expected, mutations in both sites did not suppress the formation of the complexes. Thus, it is likely that SOX-B is a high-affinity SOX9-binding site whereas SOX-A is rather a low-affinity site where SOX9 is able to bind only if SOX-B is already occupied by another SOX9 molecule. This is not surprising as SOX9-A exhibits two mismatches compared with the SOX consensus sequence and as SOX9-B is a perfect SOX consensus sequence. The specificity of SOX9 binding was further confirmed by an antibody supershift of the complex of the labeled probe and the SOX9 protein obtained either from reticulocyte lysate or from HT29Cl.16E transfected with SOX9 (Figure 2e) . Moreover, chromatin immunoprecipitation in HT29 cells evidenced a SOX9 binding to this enhancer sequence (Figure 2f ). We finally tried to interfere with SOX9 endogenous activity in colonic cells using the SOX9DC206 dominant-negative mutant (Figure 2g ). Consistent with data showing a decrease of CEACAM1 expression in HT29Cl.16E cells overexpressing DC206SOX9 (Figure  1a) , the SOX9DC206 decreased the 3.1 kb promoter activity in HT29Cl16E cells by inhibiting SOX9 endogenous activity.
Besides the previously described regulatory elements in the human CEACAM1 minimal promoter (Hauck et al., 1994; Chen et al., 1996) , the present data report the binding of SOX9 to an additional regulatory element located 1.4 kb upstream of the coding sequence.
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Identification of a SOX9 binding site in the rat and mouse CEACAM1 promoters
The human and rat CEACAM1 promoters (Hauck et al., 1994; Najjar et al., 1996) exhibit no homology (GenBank accession nos. X67277 and U2720, respectively), raising the question of the ability of SOX9 to regulate the rat CEACAM1 gene. A luciferase reporter plasmid containing the functional promoter of the rat CEACAM1 (À1609 to À21) (Najjar et al., 1996) exhibited a basal activity in HT29Cl.16E human cells that was increased by a co-transfected SOX9 (not shown). We analysed the (À1609 to À21) sequence and found the AGAACAATGA sequence in position À242 to À233. This sequence displays only one mismatch with the SOX9 optimal binding sequence (AGAACAATGG) previously determined by random oligonucleotide selection assay (Mertin et al., 1999) ( Supplementary Figure 2) . Thus a (À289 to À21) fragment was subcloned into the pGl3 basic plasmid to generate the R(À289/À21)wt luc reporter. When cotransfected with SOX9 in HT29Cl.16E cells, the luciferase activity of this reporter increased 12.6-fold (Figure 3a) . The SOX9 optimal sequence AGAA- Figure 3 SOX9 activates the rat (a) and mouse CEACAM1 promoters (b). (a) HT29.Cl16E cells were transfected with pGL3 basic vector containing a fragment (À289 to À21) of the rat CEACAM1 promoter (R(À289/À21)wt luc) or a fragment of the rat promoter in which the putative SOX9-binding site was mutated (R(À289/À21)bam luc). (b) HT29.Cl16E cells were transfected with the pGL3 basic vector containing a fragment (À331 to À3) of the mouse CEACAM1 promoter (M(À331/À3)wt luc). (c and d) SOX9 employs p300 as transcriptional co-activator of the CEACAM1 promoter. (c) HT29.Cl16E cells were transfected with reporter plasmids containing the functional 3.1-kb human CEACAM1 promoter, pGL3-Promoter vector containing a fragment (À1597 to À1032) of the human CEACAM1 promoter (H(À1597/À1032)wt luc) or with a fragment in which an EcoR1 restriction site is substituted the putative SOX9-binding sequence (H(À1597/À1032)eco luc). (d) HT29.Cl16E cells were transfected with the pGL3 basic vector containing a fragment (À289 to À21) of the rat CEACAM1 promoter (R(À289/À21)wt luc) or a fragment of the rat promoter in which the putative SOX9-binding site was mutated (R(À289/À21)bam luc). Luciferase activities of the reporters co-transfected with pcDNA3 empty vector were arbitrarily set to onefold increase. Fold increases are indicated as means ± s.e., data were analysed using the Student's t-test, P-values are indicated (n ¼ 3). CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1.
SOX9 regulates CEACAM1 expression in the intestine H Zalzali et al CAATGG contains the SOX core-binding element, AACAAT. To assess the functional significance of the AGAACAATGA sequence identified in the rat CEA-CAM1 promoter (À242 to À233), we substituted the AACAAT SOX core-binding element by GATCCT in the (À289 to À21) fragment to generate the R(À289/ À21)bam luc reporter. When co-transfected with SOX9, the luciferase activity of this reporter was not significantly modified (Figure 3a) , suggesting that the SOX9-dependent regulation of the rat CEACAM1 transcription is mediated through an interaction of SOX9 with the AGAACAATGA nucleotide sequence.
We then sought to align the nucleotide sequence of the mouse promoter (GenBank accession no. AF287911) with the rat promoter sequence (Supplementary Figure 2 ). We found one mismatch with the rat SOX9-binding site; AGAACACTGA in position À217 to À208 of the mouse promoter instead of AGAA-CAATGA in the rat promoter. A (À331 to À3) DNA fragment of the mouse CEACAM1 promoter was PCR CEACAM1 expression is reduced in the colon epithelium of SOX9-deficient mice. (a) Colon from mice was embedded in paraffin, sectioned and stained for SOX9 using a rabbit N-terminal antibody (Notarnicola et al., 2006) . (b) An adjacent slice was stained using a rabbit anti-mouse CEACAM1 antibody (Hemmila et al., 2004) . (a and b) Hematoxylin counter stain was used, bar, 150 mm. Arrows indicate the SOX9 nuclear staining, black arrowheads indicate the CEACAM1 staining in the crypts and empty arrowheads indicate the CEACAM1 staining at the surface of the epithelium. Colon from (c) wild-type or (d) SOX9À/À mice were embedded in paraffin, sectioned and stained with hematoxylin and eosin, bars, 300 mm. CEACAM1 immunostaining (red) in the colon of wild-type mice (e) compared with SOX9 knockout mice (f) with the rabbit anti-mouse CEACAM1 antibody. Nuclei were labeled with Hoechst dye (blue). Arrows indicate crypts and arrowheads indicate the surface of the epithelium. Bars, 150 mm. CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1.
SOX9 regulates CEACAM1 expression in the intestine H Zalzali et al amplified and inserted into the pGl3 basic plasmid (M(À331/À3)wt luc). This reporter displayed a basal activity in HT29Cl.16E cells that was increased threefold when co-transfected with SOX9 (Figure 3b ), suggesting that SOX9 is also able to regulate the mouse CEACAM1 gene.
The transactivation of CEACAM1 gene by SOX9 is enhanced by co-expression of p300
The ubiquitously distributed histone acetyl transferase p300 is a co-activator of SOX9 for the control of cartilage tissue-specific gene expression, and SOX9 associates with p300 through its C-terminal activation domain (Tsuda et al., 2003) . Thus, we investigated a possible SOX9 co-activator function for p300 in the control of the CEACAM1 promoter in colonic cells. As shown in Figure 3c , p300 enhanced SOX9 transcriptional activity of the 3.1 kb reporter (p3.1sluc) and the H(À1597/À1032)wt luc reporter, whereas the luciferase activity of the reporter missing the SOX9-binding site (H(À1597/À1032)eco luc) was unaffected. A similar effect of p300 was observed with the rat CEACAM1 promoter (Figure 3d ), leading to the conclusion that p300 acts as a co-activator of SOX9 for CEACAM1 gene in colonic cells.
CEACAM1 expression is reduced in the colon of SOX9-deficient mice
Consistent with earlier studies (Leung et al., 2006) , CEACAM1 staining in wild-type mice was observed in differentiated cells at the surface of the colon epithelium as well as in proliferating cells at the bottom of colonic crypt (Figures 4b and e and Supplementary Figure 3b) . According to our recent data (Bastide et al., 2007) , the colon epithelium of SOX9-deficient mice displays aberrant morphology with enlarged crypts (Figure 4d ). Here, we report that the CEACAM1 immunofluorescence staining is strongly reduced in the cryptic cells of these mice (Figure 4f ). As a residual CEACAM1 staining was still visible on the surface of the epithelium of SOX9-deficient mice ( Figure 4f ) and as SOX9 is not expressed in differentiated mouse colonic cells of the surface of the epithelium (Blache et al., 2004 ) (Supplementary Figure 3a ), other transcription factors are likely involved in the regulation of the CEACAM1 gene in these cells. These data together suggest that SOX9 has a significant function in the transcriptional activation of the mouse CEACAM1 gene in undifferentiated colonic cells and that distinct molecular mechanisms are involved in the control of CEACAM1 expression in the bottom of the colonic crypts and at the surface of the colon epithelium.
To conclude, CEACAM1 is the first identified direct transcriptional target of SOX9 in the colon epithelium. Furthermore, SOX9 with its co-factor p300 is the first described transcription factor able to regulate the rat, the mouse and the human CEACAM1 promoters in colonic cells even if the rodent and the human promoter sequences are apparently unrelated.
On the one hand, the loss of expression of CEACAM1 decreases the rate of apoptotic cell death, which in turn favors the emergence of hyperplasia and an increased probability of acquiring oncogenic mutations (Nittka et al., 2004) . On the other hand, the SOX9 knockout in the mouse colon associates with hyperplasia and, as shown here, induces the decrease of CEACAM1 expression. However, the SOX9 gene is expressed in most of the colon tumors (Blache et al., 2004; Jay et al., 2005; Lu et al., 2006) as well as in all the colon carcinoma cell lines that we had previously studied (Blache et al., 2004) . In addition, we previously reported that in HT29.Cl16E and SW480 cell lines, endogenous SOX9 activity is weak (Darido et al., 2008) . Thus, the search for the correlation between a diminution of SOX9 activity and a decrease of CEACAM1 expression at some stage in the colon tumorigenesis will be, certainly, an important subject of future investigations.
